Ziextenzo (PEGfilgrastim-Bmez) Patent Expiration, LOE Window & CMS Spending

Ziextenzo (PEGfilgrastim-Bmez) by Sandoz: Biologic BLA (Purple Book Regime), 0 AB generics, $4.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSandoz
FDA Application & PathwayB761045 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$4.3M
2024 Medicare Part D Spend$2.5M
2024 Medicaid Spend$1.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel